glp 1 drugs and parkinson's disease The Emerging Role of GLP-1 RAs in Glucagon-like peptide-1 - Wikipedia
Description
A total of 225 participants were included in the modified intention-to-treat population and assigned to tirzepatide 10 mg ( n = 73), 15 mg ( n = 77), or placebo ( n = 75), alongside lifestyle modifications
Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes
Another thing, too, is these drugs, the GLP-1s, have a lot of nausea and gastrointestinal side effects, so some of these, quote, unquote, additives are claiming to help with those effects
B., Madsbad, S
2 GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease Lee J, Hong SW, Rhee EJ, Lee WY
Recent research, notably the pivotal SELECT trial, has confirmed their suitability for non-diabetic subjects with obesity and established CVD
